Amgen Enters Cancer Biologics Deal With Oxford Genome Sciences
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration is the second in recent months to involve Amgen’s XenoMouse human monoclonal antibody generating technology.
You may also be interested in...
Deal Watch: Lundbeck Acquires Chelsea As Industry Awaits Possible AstraZeneca, Allergan Buyouts
Merck sells off its consumer business to Bayer AG in a deal in which the two companies also will co-develop and co-commercialize sGC modulator drugs. Lundbeck buys out Chelsea and its recently approved dizziness drug Northera.
GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies
Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.
GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies
Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.